News archive

New research from Karolinska Institutet shows how oestrogen protects against MASLD, a fatty liver disease that has increased dramatically during the current obesity epidemic. The study, published in Molecular Systems Biology, shows how a new drug under development could become a future treatment for fatty liver disease and liver cancer.

Researchers at Karolinska Institutet have developed a method to study liver function and disease without requiring invasive procedures. After transplanting liver cells into the eye of mice, the cornea can be used as a window into the body to monitor liver health over time. The study is published in the journal Nature Communications.

Ozempic and other GLP1 agonists are associated with a reduced risk of developing cirrhosis and liver cancer in people with type 2 diabetes and chronic liver disease, according to a nationwide study from Karolinska Institutet published in the journal Gut.

Close relatives of people with metabolic-associated fatty liver disease have a higher risk of developing liver cancer and dying from liver-related diseases, according to a national study from Karolinska Institutet published in The Journal of Hepatology. This means that family members could also benefit from the lifestyle advice that is currently only given to patients, the researchers conclude.

There is currently no drug for treating non-alcoholic fatty liver disease, which affects many people with type 2 diabetes and which can result in other serious liver diseases. A study led by researchers from Karolinska Institutet has now identified a drug candidate for the treatment of fatty liver. The preclinical study, published in the Journal of Hepatology, indicates that an antibody that blocks the protein VEGF-B presents a possible therapeutic option for fatty liver disease.

A new immunological treatment against hepatitis B and D viruses, both of which can cause liver cancer, shows promising results in animal models. Results from the treatment, which is being developed by researchers at Karolinska Institutet, have been published in the journal Gut.

In a new study, researchers at Karolinska Institutet have identified the presence of a specific connection between a protein and an lncRNA molecule in liver cancer. By increasing the presence of the lncRNA molecule, the fat depots of the tumor cell decrease, which causes the division of tumor cells to cease, and they eventually die. The study, published in the journal Gut, contributes to increased knowledge that can add to a better diagnosis and future cancer treatments.

Researchers at Karolinska Institutet have analysed and described in detail the immune cells residing in the human bile duct. The findings may pave the way for new treatment strategies against disorders of the bile duct, which are often linked to immunological processes. The study is published in the journal Science Translational Medicine.

Non-alcoholic fatty liver disease, NAFLD, is associated with several health risks. According to a new registry study led by researchers at Karolinska Institutet in Sweden, NAFLD is linked to a 17-fold increased risk of liver cancer. The findings, published in Hepatology, underscore the need for improved follow-up of NAFLD patients with the goal of reducing the risk of cancer.

Liver transplantation is currently the only treatment available for the severe liver disease PSC. Now, however, researchers at Karolinska Institutet and Oslo University have discovered the first reported genetic mutation that causes PSC. The study, which is published in Science Translational Medicine, opens new paths to future treatments.

Non-alcoholic fatty liver disease, NAFLD, affects nearly one in four adults in Europe and the U.S. Earlier research has demonstrated an increased risk of death in patients with NAFLD and advanced fibrosis or cirrhosis. Now, researchers at Karolinska Institutet in Sweden and Massachusetts General Hospital in the U.S. show that mortality increases with disease severity, but even mild fatty liver disease is linked to higher mortality. The findings have been published in the scientific journal Gut.

Repeated measurements of the biomarker FIB-4 in the blood every few years can predict the risk of developing severe liver disease, according to a new study from Karolinska Institutet published in the Journal of Hepatology. The risk of liver cirrhosis increases if the levels of this biomarker rise between two testing occasions.

Among adults with chronic viral hepatitis at high risk of liver cancer, those who took low-dose aspirin long-term were less likely to develop liver cancer or to die from liver-related causes. The findings come from a study published in the New England Journal of Medicine and conducted by a team led by investigators at Karolinska Institutet and Örebro University Hospital in Sweden and Massachusetts General Hospital in the U.S.

Researchers at Karolinska Institutet in Sweden have identified a molecular pathway that when silenced could restore the normal function of immune cells in people with fatty liver disease. The findings could lead to new strategies for treating the condition, which is a major health risk for people with obesity. The study is published in the scientific journal Science Translational Medicine.

While blood samples can reliably identify people with a low risk of developing severe liver disease, better methods are needed in primary care for identifying people in most need of care. These are some of the conclusions of a large registry-based study by researchers at Karolinska Institutet published in the esteemed journal Gastroenterology.

People who inject drugs and who are female, homeless or amphetamine users often share needles and syringes, and consequently run a higher risk of infection hepatitis C virus infection that affect the liver. However, as a new doctoral thesis from Karolinska Institutet demonstrates, early contact with a needle-exchange programme can have a protective effect.

Approximately one out of every ten people with hepatitis B are coinfected with hepatitis D, which is among the most serious liver conditions. Researchers at Karolinska Institutet and their German colleagues have described the impact of chronic hepatitis D on parts of the immune system. The study was published in the Journal of Hepatology.

Acute porphyria is a group of uncommon diseases that can cause severe, potentially life-threatening attacks of abdominal pain, nausea, vomiting and paralysis. Liver transplantation is currently the only effective treatment available for the most seriously afflicted patients. A clinical trial conducted in collaboration with researchers at Karolinska Institutet in Sweden now shows that a new drug candidate can prevent attacks in these patients. The study is published in The New England Journal of